<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7305919\results\search\disease\results.xml">
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="as long as the COVID-19 resource centre remains active. Keywords" exact="adult" post="respiratory distress syndrome coagulopathy COVID-19 delirium pathophysiology SARS-CoV-2 thromboembolism"/>
  <result pre="long as the COVID-19 resource centre remains active. Keywords adult" exact="respiratory" post="distress syndrome coagulopathy COVID-19 delirium pathophysiology SARS-CoV-2 thromboembolism Since"/>
  <result pre="the COVID-19 resource centre remains active. Keywords adult respiratory distress" exact="syndrome" post="coagulopathy COVID-19 delirium pathophysiology SARS-CoV-2 thromboembolism Since it emerged"/>
  <result pre="COVID-19 resource centre remains active. Keywords adult respiratory distress syndrome" exact="coagulopathy" post="COVID-19 delirium pathophysiology SARS-CoV-2 thromboembolism Since it emerged in"/>
  <result pre="centre remains active. Keywords adult respiratory distress syndrome coagulopathy COVID-19" exact="delirium" post="pathophysiology SARS-CoV-2 thromboembolism Since it emerged in December 2019,"/>
  <result pre="pathophysiology SARS-CoV-2 thromboembolism Since it emerged in December 2019, severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread to all"/>
  <result pre="SARS-CoV-2 thromboembolism Since it emerged in December 2019, severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) has spread to all parts"/>
  <result pre="thromboembolism Since it emerged in December 2019, severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) has spread to all parts of"/>
  <result pre="people and directly causing more than 340 000 deaths.1 Coronavirus" exact="disease" post="2019 (COVID-19), the disease caused by SARS-CoV-2, was initially"/>
  <result pre="more than 340 000 deaths.1 Coronavirus disease 2019 (COVID-19), the" exact="disease" post="caused by SARS-CoV-2, was initially viewed as primarily a"/>
  <result pre="disease caused by SARS-CoV-2, was initially viewed as primarily a" exact="respiratory" post="disease, in some cases leading to a viral pneumonia."/>
  <result pre="primarily a respiratory disease, in some cases leading to a" exact="viral pneumonia." post="It is now recognised as a complex disorder affecting"/>
  <result pre="to intensive care, a substantial proportion will die. This new" exact="disease" post="has generated a surge of research, with more than"/>
  <result pre="anaesthetists and intensive care specialists caring for patients with COVID-19." exact="Infection" post="and host defence COVID-19 starts when SARS-CoV-2 is transmitted"/>
  <result pre="or oral ingestion of virus-containing droplets. The virus likely enters" exact="epithelial" post="cells in the nasal or oral cavity through SARS-CoV-2"/>
  <result pre="(Fig 1 ). Virusâ€&quot;receptor binding results in fusion of the" exact="viral" post="envelope and cell membranes with entry of the viral"/>
  <result pre="the viral envelope and cell membranes with entry of the" exact="viral" post="nucleocapsid into the cell enabling viral mRNA to hijack"/>
  <result pre="with entry of the viral nucleocapsid into the cell enabling" exact="viral" post="mRNA to hijack host cell ribosomes to translate viral"/>
  <result pre="enabling viral mRNA to hijack host cell ribosomes to translate" exact="viral" post="code, thereby leading to generation of viral proteins and"/>
  <result pre="ribosomes to translate viral code, thereby leading to generation of" exact="viral" post="proteins and ultimately virus replication.3 Initially, there is local"/>
  <result pre="Initially, there is local propagation of the virus and a" exact="limited" post="innate immune response, but at this stage, infected individuals"/>
  <result pre="but at this stage, infected individuals can already infect others." exact="Viral" post="load is highest around the time of symptom onset"/>
  <result pre="transmissibility of the virus. SARS-CoV-2 propagates and travels down the" exact="respiratory" post="tract, and a more robust innate immune response is"/>
  <result pre="innate immune response is triggered, characterised by the occurrence of" exact="systemic" post="pro-inflammatory cytokines and activated immune cells. By then, COVID-19"/>
  <result pre="manifest with, in most cases, self-limiting mild-to-moderate symptoms of an" exact="upper respiratory tract infection" post="and general symptoms, such as myalgia and fatigue. In"/>
  <result pre="with, in most cases, self-limiting mild-to-moderate symptoms of an upper" exact="respiratory" post="tract infection and general symptoms, such as myalgia and"/>
  <result pre="most cases, self-limiting mild-to-moderate symptoms of an upper respiratory tract" exact="infection" post="and general symptoms, such as myalgia and fatigue. In"/>
  <result pre="spike protein binding with angiotensin-converting enzyme 2 (ACE2) receptor enables" exact="viral" post="envelope fusion with the host cell membrane and subsequent"/>
  <result pre="with the host cell membrane and subsequent entry of the" exact="viral" post="nucleocapsid into the cell. In the most severely affected"/>
  <result pre="interleukins), granulocyte colony-stimulating factor, and several chemokines.5 This pattern mimics" exact="secondary" post="haemophagocytic lymphohistiocytosis, an under-recognised hyperinflammatory syndrome characterised by fulminant"/>
  <result pre="chemokines.5 This pattern mimics secondary haemophagocytic lymphohistiocytosis, an under-recognised hyperinflammatory" exact="syndrome" post="characterised by fulminant hypercytokinaemia and multiorgan failure. It also"/>
  <result pre="hypercytokinaemia and multiorgan failure. It also resembles the cytokine release" exact="syndrome" post="that is seen as a complication of chimaeric antigen"/>
  <result pre="monoclonal anti-soluble IL-6 receptor antibody (tocilizumab) has been proposed.6 COVID-19" exact="coagulopathy" post="and thromboembolic complications Severe COVID-19 causes a specific coagulopathy"/>
  <result pre="antibody (tocilizumab) has been proposed.6 COVID-19 coagulopathy and thromboembolic complications" exact="Severe" post="COVID-19 causes a specific coagulopathy that is reminiscent of,"/>
  <result pre="COVID-19 coagulopathy and thromboembolic complications Severe COVID-19 causes a specific" exact="coagulopathy" post="that is reminiscent of, but also distinct from, other"/>
  <result pre="coagulopathy that is reminiscent of, but also distinct from, other" exact="systemic" post="coagulopathies associated with severe infections, such as disseminated intravascular"/>
  <result pre="from, other systemic coagulopathies associated with severe infections, such as" exact="disseminated intravascular coagulation" post="or thrombotic microangiopathy.7 Pro-inflammatory cytokines, in particular IL-6, stimulate"/>
  <result pre="express tissue factor, leading to thrombin generation, thereby initiating a" exact="systemic" post="coagulopathy. Superimposed on this low-grade coagulation activation, direct infection"/>
  <result pre="a systemic coagulopathy. Superimposed on this low-grade coagulation activation, direct" exact="infection" post="of endothelial cells causes release of plasminogen activator (explaining"/>
  <result pre="the consequent deposit of microvascular platelet thrombi, especially in affected" exact="pulmonary" post="vessels.9 Direct viral infection of endothelial cells, which express"/>
  <result pre="of microvascular platelet thrombi, especially in affected pulmonary vessels.9 Direct" exact="viral infection" post="of endothelial cells, which express ACE2 enabling entry of"/>
  <result pre="microvascular platelet thrombi, especially in affected pulmonary vessels.9 Direct viral" exact="infection" post="of endothelial cells, which express ACE2 enabling entry of"/>
  <result pre="result in widespread endothelial dysfunction associated with recruitment of a" exact="vascular" post="inflammatory response, which is more exaggerated in patients with"/>
  <result pre="inflammatory response, which is more exaggerated in patients with pre-existent" exact="vascular" post="disease.8 The simultaneous presence of vascular inflammation and coagulopathy"/>
  <result pre="in patients with pre-existent vascular disease.8 The simultaneous presence of" exact="vascular" post="inflammation and coagulopathy might explain the high incidence of"/>
  <result pre="pre-existent vascular disease.8 The simultaneous presence of vascular inflammation and" exact="coagulopathy" post="might explain the high incidence of thromboembolic complications in"/>
  <result pre="been closely associated with thrombotic complications and increased mortality.10 These" exact="systemic" post="inflammatory responses manifest as a varied and wide-ranging clinical"/>
  <result pre="ICU management to support life. COVID-19 and the lungs SARS-CoV-2" exact="infection" post="is associated with three main types of lung damage."/>
  <result pre="main types of lung damage. The typical clinical manifestation is" exact="viral pneumonia," post="seen in the early stages on CT imaging as"/>
  <result pre="seen in the early stages on CT imaging as small" exact="focal" post="areas of ground-glass opacity (GGO). These changes are typically"/>
  <result pre="ground-glass opacity (GGO). These changes are typically prominent in the" exact="peripheral" post="lung bases and are bilateral in 75% of patients."/>
  <result pre="are typically prominent in the peripheral lung bases and are" exact="bilateral" post="in 75% of patients. Lymphadenopathy, pleural effusions, and lung"/>
  <result pre="lung bases and are bilateral in 75% of patients. Lymphadenopathy," exact="pleural" post="effusions, and lung nodules are uncommon (&amp;lt;5%).11 Patients can"/>
  <result pre="of lung opacification support the notion that loss of regional" exact="pulmonary" post="vasoconstriction contributes to these pathophysiological changes, but the mechanism"/>
  <result pre="dyspnoeaâ€™ is observed, a feature also described in other severe" exact="viral" post="pneumonias, including pandemic influenza (H1N1) in 1918. FigureÂ 2"/>
  <result pre="pandemic influenza (H1N1) in 1918. FigureÂ 2 illustrates a plain" exact="chest" post="radiograph of COVID-19 pneumonia and CT of COVID-19 pneumonitis"/>
  <result pre="1918. FigureÂ 2 illustrates a plain chest radiograph of COVID-19" exact="pneumonia" post="and CT of COVID-19 pneumonitis and acute respiratory distress"/>
  <result pre="radiograph of COVID-19 pneumonia and CT of COVID-19 pneumonitis and" exact="acute" post="respiratory distress syndrome (ARDS). Fig 2 (a) Plain chest"/>
  <result pre="of COVID-19 pneumonia and CT of COVID-19 pneumonitis and acute" exact="respiratory" post="distress syndrome (ARDS). Fig 2 (a) Plain chest radiograph"/>
  <result pre="pneumonia and CT of COVID-19 pneumonitis and acute respiratory distress" exact="syndrome" post="(ARDS). Fig 2 (a) Plain chest radiograph of COVID-19"/>
  <result pre="and acute respiratory distress syndrome (ARDS). Fig 2 (a) Plain" exact="chest" post="radiograph of COVID-19 pneumonia. (b) Chest CT of COVID-19"/>
  <result pre="Chest CT of COVID-19 pneumonitis. (c) Chest CT of COVID-19" exact="acute" post="respiratory distress syndrome. A second manifestation that occurs in"/>
  <result pre="CT of COVID-19 pneumonitis. (c) Chest CT of COVID-19 acute" exact="respiratory" post="distress syndrome. A second manifestation that occurs in a"/>
  <result pre="damage, with desquamation of alveolar cells, hyaline membrane formation, and" exact="pulmonary" post="oedema, is manifest as ARDS, with widespread bilateral consolidation"/>
  <result pre="formation, and pulmonary oedema, is manifest as ARDS, with widespread" exact="bilateral" post="consolidation or GGO on imaging accompanied by progression to"/>
  <result pre="consolidation or GGO on imaging accompanied by progression to hypoxaemic" exact="respiratory" post="failure.11 This stage corresponds with findings of decreased lung"/>
  <result pre="compliance, high right-to-left shunting, and high lung recruitability.12Postmortem findings include" exact="diffuse" post="alveolar damage with patchy inflammation dominated by lymphocytes (CD3-,"/>
  <result pre="cells, and few CD20-positive B cells) and thrombi in small" exact="pulmonary" post="arteries.13 These different lung injuries warrant different management strategies."/>
  <result pre="These different lung injuries warrant different management strategies. Patients with" exact="viral pneumonia" post="may tolerate higher tidal volumes (7â€&quot;9 ml kgâˆ’1) than"/>
  <result pre="different lung injuries warrant different management strategies. Patients with viral" exact="pneumonia" post="may tolerate higher tidal volumes (7â€&quot;9 ml kgâˆ’1) than"/>
  <result pre="kgâˆ’1) than recommended for ARDS (6 ml kgâˆ’1) along with" exact="lower" post="than recommended levels of PEEP.14 In contrast, the ARDS-like"/>
  <result pre="ventilatory support, such as CPAP, can enable some patients with" exact="viral pneumonia" post="and relatively normal lung compliance to avoid invasive mechanical"/>
  <result pre="support, such as CPAP, can enable some patients with viral" exact="pneumonia" post="and relatively normal lung compliance to avoid invasive mechanical"/>
  <result pre="position, according to medical advice, in conscious patients receiving noninvasive" exact="respiratory" post="support.15 The third type of lung injury arises from"/>
  <result pre="respiratory support.15 The third type of lung injury arises from" exact="venous thromboembolism" post="(VTE), including pulmonary emboli. Despite routine thromboprophylaxis, studies from"/>
  <result pre="type of lung injury arises from venous thromboembolism (VTE), including" exact="pulmonary" post="emboli. Despite routine thromboprophylaxis, studies from France, Italy, and"/>
  <result pre="Netherlands report VTE in 35â€&quot;47% of ICU-treated patients.16 The British" exact="Thoracic" post="Society suggests higher doses of thromboprophylaxis for these patients,"/>
  <result pre="for these patients, whilst noting the likely increased risk of" exact="bleeding" post="with such an approach and the absence of clinical"/>
  <result pre="increased risk of bleeding with such an approach and the" exact="absence of" post="clinical trial evidence. In the event of unexpected clinical"/>
  <result pre="index of suspicion for VTE is warranted. COVID-19 and the" exact="heart" post="The basic mechanisms for viral infection and replication described"/>
  <result pre="is warranted. COVID-19 and the heart The basic mechanisms for" exact="viral infection" post="and replication described previously have specific relevance with regard"/>
  <result pre="warranted. COVID-19 and the heart The basic mechanisms for viral" exact="infection" post="and replication described previously have specific relevance with regard"/>
  <result pre="replication described previously have specific relevance with regard to the" exact="cardiovascular" post="system. The two groups of patients particularly at risk"/>
  <result pre="The two groups of patients particularly at risk of severe" exact="disease" post="are those with a history of either hypertension or"/>
  <result pre="of severe disease are those with a history of either" exact="hypertension" post="or coronary artery disease.17 One explanation might be that"/>
  <result pre="or angiotensin receptor blocker drugs have an impact on COVID-19" exact="disease" post="remains unclear, and at present, it is recommended that"/>
  <result pre="occur in two forms: direct cardiac injury and indirect damage" exact="secondary" post="to haemodynamic compromise. Even during the early phase of"/>
  <result pre="to haemodynamic compromise. Even during the early phase of mild" exact="symptomatic" post="disease, cardiac enzyme release can be observed, indicating myocardial"/>
  <result pre="cardiac enzyme release is a strong predictor of mortality.19 COVID-19" exact="myocarditis" post="can mimic myocardial infarction, and distinction of myocardial infarction"/>
  <result pre="is a strong predictor of mortality.19 COVID-19 myocarditis can mimic" exact="myocardial infarction," post="and distinction of myocardial infarction and myocarditis can be"/>
  <result pre="mortality.19 COVID-19 myocarditis can mimic myocardial infarction, and distinction of" exact="myocardial infarction" post="and myocarditis can be challenging with some patients presenting"/>
  <result pre="can mimic myocardial infarction, and distinction of myocardial infarction and" exact="myocarditis" post="can be challenging with some patients presenting with chest"/>
  <result pre="and myocarditis can be challenging with some patients presenting with" exact="chest" post="pain as the primary symptoms in the absence of"/>
  <result pre="challenging with some patients presenting with chest pain as the" exact="primary" post="symptoms in the absence of pyrexia and other disease"/>
  <result pre="presenting with chest pain as the primary symptoms in the" exact="absence of" post="pyrexia and other disease manifestations.22 During the early experience"/>
  <result pre="the primary symptoms in the absence of pyrexia and other" exact="disease" post="manifestations.22 During the early experience of the disease, patients"/>
  <result pre="therefore related to myocardial damage rather than arrhythmogenicity of the" exact="disease" post="itself.23 Therapies that produce QT prolongation have been associated"/>
  <result pre="fibrillation,25 but whilst arrhythmias do occur in 16% of patients," exact="atrial fibrillation" post="only makes up a proportion of this and is"/>
  <result pre="but whilst arrhythmias do occur in 16% of patients, atrial" exact="fibrillation" post="only makes up a proportion of this and is"/>
  <result pre="remarkable given the haemodynamic and inflammatory stress that COVID-19 presents." exact="Pulmonary" post="embolus in COVID-19 is relatively frequent and can cause"/>
  <result pre="embolus in COVID-19 is relatively frequent and can cause catastrophic" exact="cardiovascular" post="collapse. Patients with ARDS are vulnerable to pulmonary oedema,"/>
  <result pre="cause catastrophic cardiovascular collapse. Patients with ARDS are vulnerable to" exact="pulmonary" post="oedema, but in COVID-19, maintaining a negative fluid balance"/>
  <result pre="maintaining a negative fluid balance increases thrombogenicity and exacerbates the" exact="cardiovascular" post="collapse associated with pulmonary hypertension. As the right heart"/>
  <result pre="a negative fluid balance increases thrombogenicity and exacerbates the cardiovascular" exact="collapse" post="associated with pulmonary hypertension. As the right heart begins"/>
  <result pre="balance increases thrombogenicity and exacerbates the cardiovascular collapse associated with" exact="pulmonary" post="hypertension. As the right heart begins to fail in"/>
  <result pre="the cardiovascular collapse associated with pulmonary hypertension. As the right" exact="heart" post="begins to fail in the face of high pulmonary"/>
  <result pre="right heart begins to fail in the face of high" exact="pulmonary" post="vascular resistance, high venous filling pressures are necessary to"/>
  <result pre="heart begins to fail in the face of high pulmonary" exact="vascular" post="resistance, high venous filling pressures are necessary to maintain"/>
  <result pre="cardiac output. Adequate hydration/fluid therapy may also mitigate risk of" exact="renal failure," post="which results in 20â€&quot;30% of these patients needing renal"/>
  <result pre="these patients needing renal replacement therapy. COVID-19 and the kidneys" exact="Renal" post="damage may result from direct infection of kidney cells"/>
  <result pre="COVID-19 and the kidneys Renal damage may result from direct" exact="infection" post="of kidney cells by SARS-CoV-2 or indirect harm secondary"/>
  <result pre="direct infection of kidney cells by SARS-CoV-2 or indirect harm" exact="secondary" post="to intensive care interventions required to manage failure of"/>
  <result pre="to manage failure of other organs. Like endothelial cells, proximal" exact="renal tubular" post="cells have ACE2 receptors, and in the kidney, both"/>
  <result pre="where reduced oral or i.v. fluid administration intended to minimise" exact="pulmonary" post="vascular congestion results in inadequate renal perfusion. Elevated PEEP"/>
  <result pre="reduced oral or i.v. fluid administration intended to minimise pulmonary" exact="vascular" post="congestion results in inadequate renal perfusion. Elevated PEEP and"/>
  <result pre="to minimise pulmonary vascular congestion results in inadequate renal perfusion." exact="Elevated" post="PEEP and high driving pressures (peakâ€&quot;mean pressure) can impair"/>
  <result pre="pressure reduce renal blood flow, an effect compounded by the" exact="cardiovascular" post="depressant effects of sedation/analgesia. COVID-19 and the brain Neurological"/>
  <result pre="by the cardiovascular depressant effects of sedation/analgesia. COVID-19 and the" exact="brain" post="Neurological complications of COVID-19 infection result from a number"/>
  <result pre="of sedation/analgesia. COVID-19 and the brain Neurological complications of COVID-19" exact="infection" post="result from a number of factors: direct invasion of"/>
  <result pre="ACE2 receptors, but the presence of these entry points in" exact="brain" post="tissue is unconfirmed29 but has been inferred.30 Animal studies"/>
  <result pre="but has been inferred.30 Animal studies have documented other coronavirus" exact="infections" post="involving the CNS,31 and in humans, SARS-CoV-1 was found"/>
  <result pre="the CNS,31 and in humans, SARS-CoV-1 was found in the" exact="brain" post="in post-mortem cases,32,33 whilst coronavirus antigen and RNA in"/>
  <result pre="cases,32,33 whilst coronavirus antigen and RNA in the CSF and" exact="brain" post="tissue outside of epidemics has been confirmed in patients"/>
  <result pre="tissue outside of epidemics has been confirmed in patients with" exact="primary" post="neurological conditions, such as multiple sclerosis.34 Several case histories"/>
  <result pre="Several case histories from the current COVID-19 pandemic suggest direct" exact="viral" post="invasion. There is increasing recognition of manifestations of neurological"/>
  <result pre="direct viral invasion. There is increasing recognition of manifestations of" exact="neurological disease," post="reported in 36% of ICU patients in a series"/>
  <result pre="of ICU patients in a series from Wuhan with severe" exact="respiratory" post="disease.35 The most common presentation in the ICU setting"/>
  <result pre="setting is delirium, which, although well reported in intensive care" exact="syndrome" post="itself,36 appears to be even more common in COVID-19"/>
  <result pre="in COVID-19 ICU patients.37 Delirium may be associated with the" exact="primary" post="disease itself, or may result from the combinations of"/>
  <result pre="COVID-19 ICU patients.37 Delirium may be associated with the primary" exact="disease" post="itself, or may result from the combinations of drug"/>
  <result pre="other neurological complications in COVID-19. Encephalopathy, presenting as headache with" exact="delirium" post="and coma, associated with cerebral oedema and non-inflammatory CSF,"/>
  <result pre="Encephalopathy, presenting as headache with delirium and coma, associated with" exact="cerebral oedema" post="and non-inflammatory CSF, was reported in about 20% of"/>
  <result pre="a combination of hypoxaemia and metabolic derangement. An inflammatory COVID" exact="encephalitis" post="has also been reported presenting as headache, fever, vomiting,"/>
  <result pre="as headache, fever, vomiting, and reduced level of consciousness. Ischaemic" exact="stroke" post="was reported in around 5% of severely ill patients"/>
  <result pre="case reports of other associated neurological presentations, including Guillainâ€&quot;BarrÃ© syndrome,40,41" exact="Miller Fisher syndrome," post="meningitis, and subarachnoid haemorrhage. Conclusions Early reports described COVID-19"/>
  <result pre="reports of other associated neurological presentations, including Guillainâ€&quot;BarrÃ© syndrome,40,41 Miller" exact="Fisher syndrome," post="meningitis, and subarachnoid haemorrhage. Conclusions Early reports described COVID-19"/>
  <result pre="neurological presentations, including Guillainâ€&quot;BarrÃ© syndrome,40,41 Miller Fisher syndrome, meningitis, and" exact="subarachnoid haemorrhage." post="Conclusions Early reports described COVID-19 as a respiratory illness,"/>
  <result pre="and subarachnoid haemorrhage. Conclusions Early reports described COVID-19 as a" exact="respiratory" post="illness, but we now know that it is a"/>
  <result pre="therapeutic arsenal against COVID-19Travel Med Infect Dis202010.1016/j.tmaid.2020.101678 7LeviM.ThachilJ.IbaT.LevyJ.Coagulation abnormalities and" exact="thrombosis" post="in patients with COVID-19 infectionLancet Haematol72020e438e44032407672 8VargaZ.FlammerA.J.SteigerP.Endothelial cell infection"/>
  <result pre="and thrombosis in patients with COVID-19 infectionLancet Haematol72020e438e44032407672 8VargaZ.FlammerA.J.SteigerP.Endothelial cell" exact="infection" post="and endotheliitis in COVID-19Lancet39520201417141832325026 9LeviM.ScullyM.SingerM.The role of ADAMTS-13 in"/>
  <result pre="and endotheliitis in COVID-19Lancet39520201417141832325026 9LeviM.ScullyM.SingerM.The role of ADAMTS-13 in the" exact="coagulopathy" post="of sepsisJÂ Thromb Haemost16201864665129337416 10TangN.LiD.WangX.SunZ.Abnormal coagulation parameters are associated"/>
  <result pre="pneumoniaJÂ Thromb Haemost18202084484732073213 11ShiH.HanX.JiangN.Radiological findings from 81 patients with COVID-19" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet Infect Dis20202042543432105637 12GattinoniL.ChiumelloD.CaironiP.COVID-19"/>
  <result pre="Wuhan, China: a descriptive studyLancet Infect Dis20202042543432105637 12GattinoniL.ChiumelloD.CaironiP.COVID-19 pneumonia: different" exact="respiratory" post="treatments for different phenotypes?Intensive Care Med4620201099110232291463 13BartonL.M.DuvalE.J.StrobergE.GhoshS.MukhopadhyayS.COVID-19 autopsies, Oklahoma,"/>
  <result pre="Med4620201099110232291463 13BartonL.M.DuvalE.J.StrobergE.GhoshS.MukhopadhyayS.COVID-19 autopsies, Oklahoma, USAAm J Clin Pathol153202072573332275742 14BrowerR.G.MatthayM.A.MorrisA.SchoenfeldD.ThompsonB.T.WheelerA.Ventilation with" exact="lower" post="tidal volumes as compared with traditional tidal volumes for"/>
  <result pre="lower tidal volumes as compared with traditional tidal volumes for" exact="acute" post="lung injury and the acute respiratory distress syndromeNÂ Engl"/>
  <result pre="with traditional tidal volumes for acute lung injury and the" exact="acute" post="respiratory distress syndromeNÂ Engl J Med34220001301130810793162 15CaputoN.D.StrayerR.J.LevitanR.Early self-proning in"/>
  <result pre="traditional tidal volumes for acute lung injury and the acute" exact="respiratory" post="distress syndromeNÂ Engl J Med34220001301130810793162 15CaputoN.D.StrayerR.J.LevitanR.Early self-proning in awake,"/>
  <result pre="experience during the COVID-19 pandemicAcad Emerg Med27202037537832320506 16MiddeldorpS.CoppensM.van HaapsT.F.Incidence of" exact="venous thromboembolism" post="in hospitalized patients with COVID-19JÂ Thromb Haemost202010.1111/jth.14888Advance Access published"/>
  <result pre="17YangX.YuY.XuJ.Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational studyLancet Respir"/>
  <result pre="antihypertensives (angiotensin receptor blockers and angiotensin-converting enzyme inhibitors) in coronavirus" exact="disease" post="2019Mayo Clin Proc9520201222123032376099 19InciardiR.M.AdamoM.LupiL.Characteristics and outcomes of patients hospitalized"/>
  <result pre="Proc9520201222123032376099 19InciardiR.M.AdamoM.LupiL.Characteristics and outcomes of patients hospitalized for COVID-19 and" exact="cardiac disease" post="in Northern ItalyEur Heart J4120201821182932383763 20FriedJ.A.RamasubbuK.BhattR.The variety of cardiovascular"/>
  <result pre="19InciardiR.M.AdamoM.LupiL.Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac" exact="disease" post="in Northern ItalyEur Heart J4120201821182932383763 20FriedJ.A.RamasubbuK.BhattR.The variety of cardiovascular"/>
  <result pre="patients hospitalized for COVID-19 and cardiac disease in Northern ItalyEur" exact="Heart" post="J4120201821182932383763 20FriedJ.A.RamasubbuK.BhattR.The variety of cardiovascular presentations of COVID-19Circulation14120201930193632243205 21SalaS.PerettoG.GramegnaM.Acute"/>
  <result pre="cardiac disease in Northern ItalyEur Heart J4120201821182932383763 20FriedJ.A.RamasubbuK.BhattR.The variety of" exact="cardiovascular" post="presentations of COVID-19Circulation14120201930193632243205 21SalaS.PerettoG.GramegnaM.Acute myocarditis presenting as a reverse"/>
  <result pre="Heart J4120201821182932383763 20FriedJ.A.RamasubbuK.BhattR.The variety of cardiovascular presentations of COVID-19Circulation14120201930193632243205 21SalaS.PerettoG.GramegnaM.Acute" exact="myocarditis" post="presenting as a reverse Tako-Tsubo syndrome in a patient"/>
  <result pre="presentations of COVID-19Circulation14120201930193632243205 21SalaS.PerettoG.GramegnaM.Acute myocarditis presenting as a reverse Tako-Tsubo" exact="syndrome" post="in a patient with SARS-CoV-2 respiratory infectionEur Heart J4120201861186232267502"/>
  <result pre="as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2" exact="respiratory" post="infectionEur Heart J4120201861186232267502 22KangY.ChenT.MuiD.Cardiovascular manifestations and treatment considerations in"/>
  <result pre="reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infectionEur" exact="Heart" post="J4120201861186232267502 22KangY.ChenT.MuiD.Cardiovascular manifestations and treatment considerations in covid-19Heart202010.1136/heartjnl-2020-317056Advance Access"/>
  <result pre="32354800 23GuoT.FanY.ChenM.Cardiovascular implications of fatal outcomes of patients with coronavirus" exact="disease" post="2019 (COVID-19)JAMA Cardiol202010.1001/jamacardio.2020.1017Advance Access published on March 27, 2020."/>
  <result pre="2020. PMID 32219356 24ChorinE.DaiM.ShulmanE.The QT interval in patients with SARS-CoV-2" exact="infection" post="treated with hydroxychloroquine/azithromycinNature Med202010.1101/2020.04.02.20047050v1Preprint posted on April 3, 2020."/>
  <result pre="hydroxychloroquine/azithromycinNature Med202010.1101/2020.04.02.20047050v1Preprint posted on April 3, 2020. PMID 32488217 25MossT.J.CallandJ.F.EnfieldK.B.New-onset" exact="atrial fibrillation" post="in the critically illCrit Care Med45201779079728296811 26WangD.HuB.HuC.Clinical characteristics of"/>
  <result pre="Med202010.1101/2020.04.02.20047050v1Preprint posted on April 3, 2020. PMID 32488217 25MossT.J.CallandJ.F.EnfieldK.B.New-onset atrial" exact="fibrillation" post="in the critically illCrit Care Med45201779079728296811 26WangD.HuB.HuC.Clinical characteristics of"/>
  <result pre="26WangD.HuB.HuC.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in Wuhan, ChinaJAMA323202010611069 27SuH.YangM.WanC.Renal histopathological analysis of 26 postmortem"/>
  <result pre="28van den AkkerJ.P.EgalM.GroeneveldA.B.Invasive mechanical ventilation as a risk factor for" exact="acute" post="kidney injury in the critically ill: a systematic review"/>
  <result pre="den AkkerJ.P.EgalM.GroeneveldA.B.Invasive mechanical ventilation as a risk factor for acute" exact="kidney injury" post="in the critically ill: a systematic review and meta-analysisCrit"/>
  <result pre="hostâ€&quot;virus interaction, and proposed neurotropic mechanismsACS Chem Neurosci11202099599832167747 30De FeliceF.G.Tovar-MollF.MollJ.MunozD.P.FerreiraS.T.Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) and the central nervous"/>
  <result pre="interaction, and proposed neurotropic mechanismsACS Chem Neurosci11202099599832167747 30De FeliceF.G.Tovar-MollF.MollJ.MunozD.P.FerreiraS.T.Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) and the central nervous systemTrends"/>
  <result pre="and proposed neurotropic mechanismsACS Chem Neurosci11202099599832167747 30De FeliceF.G.Tovar-MollF.MollJ.MunozD.P.FerreiraS.T.Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) and the central nervous systemTrends Neurosci43202035535732359765"/>
  <result pre="Access published on April 25, 2020. PMID 32333487 32GuJ.GongE.ZhangB.Multiple organ" exact="infection" post="and the pathogenesis of SARSJÂ Exp Med202200541542416043521 33ZhangQ.L.DingY.Q.HouJ.L.Detection of"/>
  <result pre="and the pathogenesis of SARSJÂ Exp Med202200541542416043521 33ZhangQ.L.DingY.Q.HouJ.L.Detection of severe" exact="acute" post="respiratory syndrome (SARS)-associated coronavirus RNA in autopsy tissues with"/>
  <result pre="the pathogenesis of SARSJÂ Exp Med202200541542416043521 33ZhangQ.L.DingY.Q.HouJ.L.Detection of severe acute" exact="respiratory" post="syndrome (SARS)-associated coronavirus RNA in autopsy tissues with in"/>
  <result pre="pathogenesis of SARSJÂ Exp Med202200541542416043521 33ZhangQ.L.DingY.Q.HouJ.L.Detection of severe acute respiratory" exact="syndrome" post="(SARS)-associated coronavirus RNA in autopsy tissues with in situ"/>
  <result pre="Da Xue Bao23200311251127 34MurrayR.S.BrownB.BrianD.CabiracG.F.Detection of coronavirus RNA and antigen in" exact="multiple sclerosis" post="brainAnn Neurol3119925255331596089 35MaoL.WangM.ChenS.Neurological manifestations of hospitalized patients with COVID-19"/>
  <result pre="J Med38220202268227032294339 38ChenT.WuD.ChenH.Clinical characteristics of 113 deceased patients with coronavirus" exact="disease" post="2019: retrospective studyBMJ3682020m109132217556 39LodigianiC.IapichinoG.CarenzoL.Venous and arterial thromboembolic complications in"/>
  <result pre="admitted to an academic hospital in Milan, ItalyThromb Res191202091432353746 40ScheidlE.CansecoD.D.Hadji-NaumovA.BereznaiB.Guillainâ€&quot;BarrÃ©" exact="syndrome" post="during SARS-CoV-2 pandemic: a case report and review of"/>
  <result pre="report and review of recent literatureJÂ Peripher Nerv Syst25202020420732388880 41ZhaoH.ShenD.ZhouH.LiuJ.ChenS.Guillainâ€&quot;BarrÃ©" exact="syndrome" post="associated with SARS-CoV-2 infection: causality or coincidence?Lancet Neurol19202038338432246917"/>
 </snippets>
</snippetsTree>
